All data are based on the daily closing price as of April 1, 2025
m

Medigen Vaccine Biologics

6547.TWO
1.48 USD
0.03
+2.07%

Overview

Last close
1.48 usd
Market cap
488.11M usd
52 week high
2.41 usd
52 week low
1.04 usd
Target price
3.4 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
25.0036
Price/Book Value
4.1199
Enterprise Value
430.26M usd
EV/Revenue
23.5863
EV/EBITDA
190.807

Key financials

Revenue TTM
18.78M usd
Gross Profit TTM
-6.40M usd
EBITDA TTM
-18.82M usd
Earnings per Share
-0.06 usd
Dividend
N/A usd
Total assets
133.10M usd
Net debt
N/A usd

About

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
  • Symbol
    6547.TWO
  • Exchange
    TWO
  • Isin
    TW0006547003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Ms. Yu-Ping Yang
  • Headquarter
    Zhubei City
  • Web site
    https://www.medigenvac.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top